| Biotechnology Industry | Healthcare Sector | Dr. Robert B. Huizinga CNeph(C), M.Sc., MSc(Epi), Ph.D., R.N., RN NNC CEO | TSX-V Exchange | CA4838092084 ISIN |
| CA Country | - Employees | - Last Dividend | 13 Mar 2017 Last Split | - IPO Date |
Kane Biotech Inc. is a pioneering biotechnology company that specializes in the discovery, development, and delivery of innovative solutions to combat microbial biofilms. Established in 2001 and headquartered in Winnipeg, Canada, Kane Biotech has established itself as a leader in the biofilm research field, extending its reach both nationally and internationally. The company aims to address the challenges posed by biofilms across a variety of industries, including pet oral care, wound care for animals and humans, and scalp care. Through dedicated research and development efforts, Kane Biotech has successfully translated scientific discoveries into commercial products that tackle biofilm-related issues in practical, effective ways.